Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Home Access HIV test use reveals three-times positive rate compared to national average.

This article was originally published in The Tan Sheet

Executive Summary

HOME ACCESS HIV TEST RESULTS SHOW .9% SEROPOSITIVE RATE -- three times the estimated national rate -- among 152,044 users of the over-the-counter HIV home blood test service. In its Dec. 2 "HIV Counseling & Testing Report," Hoffman Estates, Ill.-based Home Access announces data collected anonymously during pretest counseling from August 1996 through September 1997. The .9% seropositive rate is higher than the Centers for Disease Control & Prevention's recently estimated rate of .3%. The Home Access survey is intended to complement CDC's annual efforts to provide a demographic summary of HIV cases for those tested at publicly-funded sites, the company said. The seropositive rate at publicly funded sites for 1995 was 1.2%, according to CDC's report. Home Access markets the only HIV test service available OTC.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel